Evidence map›Paper›PMID 35211290›Full record

ArticleTherapeutic advances in psychopharmacology2021

Possible pharmacogenetic factors in clozapine treatment failure: a case report.

Eromona Whiskey, Graziella Romano, Matilda Elliott, Malcolm Campbell, Cholan Anandarajah, David Taylor, Koravangattu Valsraj

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Eromona WhiskeyPharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, SE5 8AZ, UK.ORCID https://orcid.org/0000-0002-6146-0073
Graziella RomanoSouth London and Maudsley NHS Foundation Trust, London, UK.
Matilda ElliottSouth London and Maudsley NHS Foundation Trust, London, UK.
Malcolm CampbellSouth London and Maudsley NHS Foundation Trust, London, UK.
Cholan AnandarajahSouth London and Maudsley NHS Foundation Trust, London, UK.
David TaylorPharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-2557-1710
Koravangattu ValsrajSouth London and Maudsley NHS Foundation Trust, London, UK.
South London and Maudsley NHS Foundation Trust · GBKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is still much to learn about the predictors of therapeutic response in psychiatry, but progress is gradually being made and precision psychiatry is an exciting and emerging subspeciality in this field. This is critically important in the treatment of refractory psychotic disorders, where clozapine is the only evidence-based treatment but only about half the patients experience an adequate response. In this case report, we explore the possible biological mechanisms underlying treatment failure and discuss possible ways of improving clinical outcomes. Further work is required to fully understand why some patients fail to respond to the most effective treatment in refractory schizophrenia. Therapeutic drug monitoring together with early pharmacogenetic testing may offer a path for some patients with refractory psychotic symptoms unresponsive to clozapine treatment.

Indexed as

case reportclozapinepharmacogeneticsplasma levelschizophreniatherapeutic drug monitoring

Identifiers

PMID35211290
PMCPMC8862186
OpenAlexW3194587721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.